First Manhattan
MRSN

First Manhattan’s Mersana Therapeutics MRSN Stock Holding History

First Manhattan’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,784
Closed -$1.87M – 1539
2023
Q2 		$1.87M Buy
+22,784
New +$3.33M 0.01% 315
2021
Q4 		– Sell
-8,723
Closed -$2.06M – 1636
2021
Q3 		$2.06M Buy
+8,723
New +$2.55M 0.01% 331

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

First Manhattan's MRSN Position: Q3 2023 in Review

First Manhattan sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 22,784 shares — an estimated $1.87M sold.

First Manhattan first reported a position in MRSN in Q3 2021 and held it in 2 quarters. The position peaked at $2.06M in Q3 2021. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • First Manhattan reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • First Manhattan sold 22,784 Mersana Therapeutics shares in Q3 2023, an estimated $1.87M.
  • First Manhattan first reported a position in Mersana Therapeutics in Q3 2021 and held it in 2 quarters.
  • First Manhattan's Mersana Therapeutics position peaked at $2.06M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on First Manhattan's 13F filing for Q3 2023, filed 14 Nov 2023.